Lyophilized Factor Xa Antidote Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant therapies face challenges with bleeding risks and the inability to rapidly reverse anticoagulant activity, particularly in cases of overdosing or urgent surgical procedures, and there is a need for stable and soluble injectable antidotes to anticoagulants like factor Xa inhibitors.
Innovation Solution
Development of lyophilized formulations of a derivative of factor Xa protein, referred to as the 'r-Antidote', which includes modifications to the Gla domain and active site, preventing assembly into a prothrombinase complex, and is stabilized with cryoprotectants and lyoprotectants like arginine, sucrose, and mannitol to maintain an amorphous phase during lyophilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If biologically active proteins are delivered by injection, then immediate therapeutic activity is achieved, but poor long-term storage, osmolality, solubility, and stability make delivery problematic
Solution Approach 1:
The patent employs lyophilization (freeze-drying) to transition the protein from liquid to solid amorphous phase for storage, then back to liquid for administration. This phase transition enables long-term stable storage while maintaining the ability to deliver immediate therapeutic activity upon reconstitution and injection
Solution Approach 2:
The patent introduces lyoprotectants (sucrose, mannitol, arginine) as intermediary substances that stabilize the protein during lyophilization and storage. These intermediaries prevent protein aggregation and degradation in the amorphous state, enabling long-term storage stability while allowing the protein to regain full activity after reconstitution
2Stability of the object's composition
If lyophilization is used to solve long-term storage issues, then storage stability is improved, but poor solubility and stability of the lyophilizate occur
Solution Approach 1:
The patent uses lyoprotectants (sucrose, mannitol, arginine) as intermediary substances that remain in the amorphous matrix during lyophilization. These intermediaries prevent protein aggregation and maintain solubility by forming a protective glassy matrix that keeps the protein soluble upon reconstitution, thus resolving both storage stability and solubility issues
Solution Approach 2:
The patent creates a composite amorphous formulation consisting of the protein, lyoprotectants (sucrose, mannitol, arginine), and other excipients. This composite material combines the stabilizing properties of multiple components to achieve both long-term storage stability and good solubility upon reconstitution
3Quantity of substance
If high concentrations of proteins are formulated, then therapeutic efficacy is improved, but protein aggregation and particle formation at hydrophobic interfaces occur
Solution Approach 1:
The patent introduces surfactants and lyoprotectants as intermediary substances that adsorb at hydrophobic interfaces and prevent protein aggregation. These intermediaries reduce surface tension and protect protein surfaces from aggregation-prone interactions, enabling high protein concentrations to be formulated without particle formation
Solution Approach 2:
The patent converts the potentially harmful effect of hydrophobic interfaces (which cause aggregation) into a beneficial outcome by using surfactants to modify these interfaces. The surfactants bind to hydrophobic regions, preventing protein-protein aggregation while maintaining the high concentration needed for therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The r-Antidote formulations provide a stable and soluble antidote that effectively neutralizes factor Xa inhibitors, reducing bleeding risks and enabling rapid reversal of anticoagulant activity without causing hemodynamic side effects, thus addressing the limitations of existing anticoagulant therapies.
Implementation Method 1
provided herein are lyophilized compositions obtainable by lyophilizing an aqueous formulation
Implementation Method 2
during freezing and lyophilization processes, it may be desired to maintain proteins in an amorphous phase with various cryoprotectants and lyoprotectants
Data Source
AI summary
The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, and a stabilizer, wherein the formulation does not collapse during lyophilization.